Inclusion Criteria:~* Males or females 50 to 90 of age inclusive.~* Diagnosis of probable AD according to
National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related
Disorders Association (NINCDS-ADRDA) criteria.~* Willing and able to provide informed consent by either the
subject or subject's legal representative.~* Willing and able to comply with study visits, treatment plan,
laboratory tests, brain imaging and other procedures.~* Subjects must have a positive 18f-AV-45 PET scan as
determined by a qualified rater.~* Mini-Mental State Examinations (MMSE) score between 10-20 inclusive.~* Must
have a study partner who is able and willing to comply with all required study procedures.~* Females must be
postmenopausal.~* Have at least eight years of education and should have previously (in pre-AD condition) been
capable of reading, writing, and communicating effectively with others in English.~* If receiving therapy with
a cholinesterase inhibitor and/or memantine, the dose of these agents has been stable for at least 4 weeks
prior to randomization~* Normal laboratory findings at baseline including CBC, chemistry panel, serum lipids,
liver functions, TSH, and vitamin B12.~* Must consent to ApoE genotyping~
